Clinical trial · no report yet · Phase 2
ATEMPT 2.0
ATEMPT 2.0: Adjuvant T-DM1 vs TH
- NCT04893109 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; HER2-positive Breast Cancer
- Interventions
- trastuzumab-emtansine; Trastuzumab SC; Paclitaxel
- Arms
- Arm A. T-DM1 followed by Trastuzumab SC · Experimental
- Arm B: Paclitaxel with Trastuzumab SC, followed by Trastuzumab SC alone · Experimental
- Enrollment
- 500 (estimated)
- Primary outcomes
- Incidence of clinically relevant toxicities (CRT)
- Disease Free Survival (DFS)
- Sponsor
- Dana-Farber Cancer Institute with Genentech, Inc.
- Start
- Jun 16, 2021
- Primary completion
- Nov 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04893109 · updated Aug 19, 2026